Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunDamage: Tirbanibulin 1% Ointment for chronically sun-damaged facial skin
2022-003326-44Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tirbanibulin in actinic keratosis (AK), sponsored by Medical University of Graz. Primary endpoint: Total clearance rate of unmasked lesions. Started Feb 2023; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2022-003326-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003326-44.